290 related articles for article (PubMed ID: 16906782)
1. Adalimumab: in psoriatic arthritis.
Simpson D; Scott LJ
Drugs; 2006; 66(11):1487-96; discussion 1497-9. PubMed ID: 16906782
[TBL] [Abstract][Full Text] [Related]
2. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH
Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
[TBL] [Abstract][Full Text] [Related]
3. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.
Kirson NY; Rao S; Birnbaum HG; Kantor E; Wei RS; Cifaldi M
J Med Econ; 2013; 16(4):479-89. PubMed ID: 23339434
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.
Genovese MC; Mease PJ; Thomson GT; Kivitz AJ; Perdok RJ; Weinberg MA; Medich J; Sasso EH;
J Rheumatol; 2007 May; 34(5):1040-50. PubMed ID: 17444593
[TBL] [Abstract][Full Text] [Related]
6. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
Mease PJ; Gladman DD; Ritchlin CT; Ruderman EM; Steinfeld SD; Choy EH; Sharp JT; Ory PA; Perdok RJ; Weinberg MA;
Arthritis Rheum; 2005 Oct; 52(10):3279-89. PubMed ID: 16200601
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT).
Mease PJ; Ory P; Sharp JT; Ritchlin CT; Van den Bosch F; Wellborne F; Birbara C; Thomson GT; Perdok RJ; Medich J; Wong RL; Gladman DD
Ann Rheum Dis; 2009 May; 68(5):702-9. PubMed ID: 18684743
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab: a review of its use in rheumatoid arthritis.
Bang LM; Keating GM
BioDrugs; 2004; 18(2):121-39. PubMed ID: 15046527
[TBL] [Abstract][Full Text] [Related]
10. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study.
Gladman DD; ; Sampalis JS; Illouz O; Guérette B
J Rheumatol; 2010 Sep; 37(9):1898-906. PubMed ID: 20595284
[TBL] [Abstract][Full Text] [Related]
11. Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials.
Mease PJ; Signorovitch J; Yu AP; Wu EQ; Gupta SR; Bao Y; Mulani PM
Dermatology; 2010; 220(1):1-7. PubMed ID: 19940437
[TBL] [Abstract][Full Text] [Related]
12. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
13. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
McInnes IB; Behrens F; Mease PJ; Kavanaugh A; Ritchlin C; Nash P; Masmitja JG; Goupille P; Korotaeva T; Gottlieb AB; Martin R; Ding K; Pellet P; Mpofu S; Pricop L;
Lancet; 2020 May; 395(10235):1496-1505. PubMed ID: 32386593
[TBL] [Abstract][Full Text] [Related]
14. Golimumab for the treatment of psoriatic arthritis.
Yang H; Epstein D; Bojke L; Craig D; Light K; Bruce I; Sculpher M; Woolacott N
Health Technol Assess; 2011 May; 15 Suppl 1():87-95. PubMed ID: 21609657
[TBL] [Abstract][Full Text] [Related]
15. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Mease PJ; van der Heijde D; Ritchlin CT; Okada M; Cuchacovich RS; Shuler CL; Lin CY; Braun DK; Lee CH; Gladman DD;
Ann Rheum Dis; 2017 Jan; 76(1):79-87. PubMed ID: 27553214
[TBL] [Abstract][Full Text] [Related]
16. [Systemic psoriasis therapy - the next step. Adalimumab].
Wozel G; Sticherling M
Hautarzt; 2007 Jun; 58(6):515-8, 520-4. PubMed ID: 17492418
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab for the treatment of severe psoriasis and psoriatic arthritis.
Papoutsaki M; Costanzo A; Chimenti MS; Chimenti S
Expert Opin Biol Ther; 2008 Mar; 8(3):363-70. PubMed ID: 18294106
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed.
van de Putte LB; Atkins C; Malaise M; Sany J; Russell AS; van Riel PL; Settas L; Bijlsma JW; Todesco S; Dougados M; Nash P; Emery P; Walter N; Kaul M; Fischkoff S; Kupper H
Ann Rheum Dis; 2004 May; 63(5):508-16. PubMed ID: 15082480
[TBL] [Abstract][Full Text] [Related]
19. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
McInnes IB; Asahina A; Coates LC; Landewé R; Merola JF; Ritchlin CT; Tanaka Y; Gossec L; Gottlieb AB; Warren RB; Ink B; Assudani D; Bajracharya R; Shende V; Coarse J; Mease PJ
Lancet; 2023 Jan; 401(10370):25-37. PubMed ID: 36493791
[TBL] [Abstract][Full Text] [Related]
20. Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPT.
Mease PJ; Heckaman M; Kary S; Kupper H
J Rheumatol; 2013 May; 40(5):647-52. PubMed ID: 23504383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
